AI Tool Linked to Lower Hospital Readmission Rates for Patients with Opioid Use Disorder

A clinical trial supported by the National Institutes of Health (NIH) has found that an artificial intelligence (AI) screening tool is as effective as human healthcare providers in identifying hospitalized patients at risk of opioid use disorder and recommending addiction specialist consultations. In addition to maintaining clinical quality, the AI-based method was associated with a significant reduction in hospital readmissions, potentially offering cost savings and improved outcomes for healthcare systems.

The study, published in Nature Medicine, was conducted at University Hospital in Madison, Wisconsin, by researchers from the University of Wisconsin School of Medicine and Public Health. It compared traditional provider-led addiction consultations to those prompted by an AI screener integrated into electronic health records. Among the 51,760 adult hospitalizations analyzed between 2021 and 2023, approximately 34% were managed using the AI tool. While the consultation rates were similar—1.51% with the AI tool versus 1.35% without—it was the difference in 30-day readmission rates that stood out. Patients in the AI group had 47% lower odds of being readmitted within a month of discharge.

The AI system worked by scanning patients’ medical records in real time and issuing alerts recommending addiction specialist referrals and withdrawal monitoring when relevant patterns were identified. These alerts were delivered directly to providers during routine chart access, prompting timely interventions. Ultimately, the study estimated that the AI-assisted approach helped prevent 16 hospital readmissions, resulting in nearly $109,000 in healthcare savings over the eight-month period in which it was used.

The results remained consistent even after adjusting for factors such as patient demographics and existing medical conditions. The cost of implementing the AI tool was outweighed by the savings from avoided readmissions, with a net cost of $6,801 per readmission averted compared to the average cost of $16,300 for a 30-day readmission. However, researchers acknowledged that broader validation is still needed, as the AI system’s performance may vary across different institutions and patient populations.

Despite these limitations, the findings highlight the potential of AI to play a more integrated role in addiction care, especially in hospital environments where manual screening can be inconsistent or overlooked. With opioid-related hospital visits continuing to rise, tools that enhance early detection and intervention for opioid use disorder may offer a critical advantage in reducing overdoses and improving treatment outcomes.

Article by multiple RFHC contributors, based upon information from a press release issued by the National Institutes of Health (NIH).

Video Spotlight